Tag Archives: Arecor Therapeutics

Lilly Partners for Cardiometabolic Drug Discovery; Insulet, 89bio, Arrowhead, and Akero Q1 ’24 Earnings; Medtronic Partners with Arecor for Implantable Pump; Senseonics Partners for Remote Care Platform; Noom Launches Movement Program for People on GLP-1RAs

A series of cardiometabolic-related news items have been observed from Lilly, Insulet, Arecor/Medtronic, Senseonics/Rimidi, 89bio, Arrowhead, Akero, and Noom. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

SAB Initiates Ph1 T1DM study; Lilly Continues Verve Investment; Arecor Expands Collaboration with Lilly; Avidity Expands CV Partnership with BMS

Four cardiometabolic-related news items have been observed from SAB Biotherapeutics, Verve/Lilly, Arecor/Lilly, and Avidity/BMS. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Arecor Initiates Ph1 Ultra-Rapid Insulin Trial in T1DM

Arecor Therapeutics announced the initiation of a Ph1 clamp study comparing its ultra-rapid insulin (AT247) to Novolog and Fiasp in T1DM patients (view CT.gov record). Recall, at EASD 2020, Arecor presented an abstract (view here) for a Ph1 study which demonstrated AT247 had a faster onset of glucose-lowering than aspart (17 vs. 50 minutes) and a greater early glucose-lowering effect compared to both aspart and faster aspart (previous FENIX insight). Below FENIX provides brief thoughts on the initiation of the Ph1 trial and Arecor’s diabetes pipeline.

This content is for Read Less members only.

Already a member? Log in here